Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05959603 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intra-wound Vancomycin Powder for Prevention of Surgical Site Infection Following Spinal Surgery

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 27, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 1, 2024 to Dec 1, 2025
    • Study completion date: Dec 1, 2025 to Dec 1, 2026
    v3
  2. Primary completion date: Dec 1, 2023 to Dec 1, 2024
    • Study completion date: Dec 1, 2024 to Dec 1, 2025
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cefazolin is given routinely pre and intraoperatively for patients undergoing spinal surgery to reduce the rate of infection. Intra-wound admission of Vancomycin powder has been suggested to reduce wound infection rates. Therefore, this study aims to compare the rate of wound-related complications between patients receiving standard treatment compared to patients receiving an addition of topical Vancomycin and to identify the optimal Vancomycin dosage. All groups will receive the recommended regimen of routine IV antibiotic prophylaxis.
Trial Details
NCT Number NCT05959603
Lead Sponsor Rabin Medical Center
Conditions
(from sponsor)		 Infection
Related terms Infections
Enrollment 363 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov